{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:45:06Z","timestamp":1790437506775,"version":"4.1.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["1K23DK123384-03"],"award-info":[{"award-number":["1K23DK123384-03"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["P30DK111024-04S2"],"award-info":[{"award-number":["P30DK111024-04S2"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["IIS to Emory University"],"award-info":[{"award-number":["IIS to Emory University"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>In participants with type 2 diabetes (T2D) and HbA1c &amp;gt;9.0\u201310.0%, guidelines recommend treatment with basal-bolus insulin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This randomized trial compared the efficacy and safety of insulin degludec and liraglutide (IDegLira) and basal-bolus among participants with high HbA1c \u22659.0\u201315.0%, previously treated with 2 or 3 oral agents and\/or basal insulin, allocated (1:1) to basal-bolus (n = 73) or IDegLira (n = 72). The primary end point was noninferiority (0.4%) in HbA1c reduction between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Among 145 participants (HbA1c 10.8% \u00b1 1.3), there was no statistically significant difference in HbA1c reduction (3.18% \u00b1 2.29 vs. 3.00% \u00b1 1.79, P = 0.65; estimated treatment difference (ETD) 0.18%, 95% CI \u22120.59, 0.94) between the IDegLira and basal-bolus groups. IDegLira resulted in significantly lower rates of hypoglycemia &amp;lt;70 mg\/dL (26% vs. 48%, P = 0.008; odds ratio 0.39, 95% CI 0.19, 0.78), and less weight gain (1.24 \u00b1 8.33 vs. 5.84 \u00b1 6.18 kg, P = 0.001; ETD \u22124.60, 95% CI \u22127.33, \u22121.87).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In participants with T2D and HbA1c \u22659.0\u201315.0%, IDegLira resulted in similar HbA1c reduction, less hypoglycemia, and less weight gain compared with the basal-bolus regimen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc22-2426","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T19:58:55Z","timestamp":1689623935000},"page":"1640-1645","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":13,"title":["A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c \u22659\u201315%: DUAL HIGH Trial"],"prefix":"10.2337","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"first","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobak","family":"Moazzami","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Scioscia","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Zambrano","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie S.","family":"Albury","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarrod","family":"Saling","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyathama","family":"Vellanki","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Pasquel","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia M.","family":"Davis","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Fayfman","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Peng","sequence":"additional","affiliation":[{"name":"2Deartment of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"2023082518543994100_B1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2023082518543994100_B2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2023082518543994100_B3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2023082518543994100_B4","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.2337\/dcS13-2011","article-title":"Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"2023082518543994100_B5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2010.04.009","article-title":"The stunned beta cell: a brief history","volume":"11","author":"Ferrannini","year":"2010","journal-title":"Cell Metab"},{"key":"2023082518543994100_B6","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"2023082518543994100_B7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1463-1326.2009.01139.x","article-title":"Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient","volume":"11","author":"Garber","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2023082518543994100_B8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"key":"2023082518543994100_B9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"},{"key":"2023082518543994100_B10","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1751-9918(10)60004-6","article-title":"Addressing barriers to initiation of insulin in patients with type 2 diabetes","volume":"4","author":"Peyrot","year":"2010","journal-title":"Prim Care Diabetes"},{"key":"2023082518543994100_B11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0145721709345773","article-title":"Barriers to insulin injection therapy: patient and health care provider perspectives","volume":"35","author":"Rubin","year":"2009","journal-title":"Diabetes Educ"},{"key":"2023082518543994100_B12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1525-1497.2005.0117.x","article-title":"Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens","volume":"20","author":"Vijan","year":"2005","journal-title":"J Gen Intern Med"},{"key":"2023082518543994100_B13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/dom.12114","article-title":"Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin","volume":"15","author":"Josse","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2023082518543994100_B14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.2016.1252","article-title":"Effect of insulin glargine up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial [published correction appears in JAMA 2016;315:2125]","volume":"315","author":"Lingvay","year":"2016","journal-title":"JAMA"},{"key":"2023082518543994100_B15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2337\/dc17-1114","article-title":"Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial","volume":"41","author":"Billings","year":"2018","journal-title":"Diabetes Care"},{"key":"2023082518543994100_B16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","article-title":"Trends in diabetes treatment and control in U.S. Adults, 1999\u20132018","volume":"384","author":"Fang","year":"2021","journal-title":"N Engl J Med"},{"key":"2023082518543994100_B17","unstructured":"Centers for Disease Control and Prevention\n          . National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Accessed 18 January 2022. Available from https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html"},{"key":"2023082518543994100_B18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"key":"2023082518543994100_B19","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/dom.13794","article-title":"A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: the SIMPLE study","volume":"21","author":"Abreu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2023082518543994100_B20","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1210\/jc.2016-3423","article-title":"Efficacy of exenatide plus pioglitazone vs basal\/bolus insulin in T2DM patients with very high HbA1c","volume":"102","author":"Abdul-Ghani","year":"2017","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/9\/1640\/733296\/dc222426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/9\/1640\/733296\/dc222426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:55:28Z","timestamp":1692989728000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/46\/9\/1640\/153419\/A-Randomized-Controlled-Trial-Comparing-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc22-2426","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}